• The primary endpoint of the trial was met
• This is the first proof of concept in patients of an anti-viral effect of γδ T cell activation
• Innate Pharma intends to develop further its program in this indication

In connection with this announcement, a conference call was organized on June 29, 2009.   
The slideshow is available here: